GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Natera Inc (NAS:NTRA) » Definitions » Total Inventories

Natera (Natera) Total Inventories

: $41 Mil (As of Dec. 2023)
View and export this data going back to 2015. Start your Free Trial

Natera's total inventories for the quarter that ended in Dec. 2023 was $41 Mil. Natera's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $41 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Natera's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $3.61.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Natera's Days Inventory for the three months ended in Dec. 2023 was 24.99.

Inventory Turnover measures how fast the company turns over its inventory within a year. Natera's Inventory Turnover for the quarter that ended in Dec. 2023 was 3.65.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Natera's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.13.


Natera Total Inventories Historical Data

The historical data trend for Natera's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Natera Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.39 20.03 26.91 35.41 40.76

Natera Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Inventories Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.41 40.68 42.69 42.08 40.76

Natera Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Natera  (NAS:NTRA) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Natera's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

Net-Net Working Capital Per Share (Q: Dec. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(878.977+0.75 * 278.289+0.5 * 40.759-676.372
-0-0)/119.581
=3.61

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Natera's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=41.4175/151.247*365 / 4
=24.99

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Natera's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=151.247 / 41.4175
=3.65

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Natera's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=41.4175 / 311.105
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Natera Total Inventories Related Terms

Thank you for viewing the detailed overview of Natera's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Natera (Natera) Business Description

Traded in Other Exchanges
N/A
Address
13011 McCallen Pass, Building A Suite 100, Austin, TX, USA, 78753
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Executives
Michael Burkes Brophy officer: Chief Financial Officer 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Steven Leonard Chapman officer: Chief Operating Officer 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Daniel Rabinowitz officer: CHIEF LEGAL OFFICER C/O NATERA, INC., 13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN TX 78753
Jonathan Sheena director, officer: Chief Technology Officer C/O NATERA, INC., 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Gail Boxer Marcus director 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Rowan E Chapman director 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Matthew Rabinowitz director, officer: Chief Executive Officer C/O NATERA, INC., 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Brinkley Ruth Williams director C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Robert Alan Schueren officer: Chief Operating Officer 7400 PASEO PADRE PARKWAY, FREMONT CA 94555
Roelof Botha director C/O SEQUOIA CAPITAL, 2800 SAND HILL RD, SUITE 101, MENLO PARK CA 94025
Herm Rosenman officer: Chief Financial Officer OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
Todd C Cozzens director ONE FEDERAL STREET, 25TH FLOOR, BOSTON MA 02110
Monica Bertagnolli director C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Roy D. Baynes director C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130